信件：肠道炎症、COVID-19 和胃肠道 ACE2-探索 RAS 抑制剂。
Letter: intestinal inflammation, COVID-19 and gastrointestinal ACE2-exploring RAS inhibitors.
机构信息
Department of Gastroenterology, Northern Hospital, Melbourne, Vic., Australia.
Department of Gastroenterology, Royal Melbourne Hospital, Melbourne, Vic., Australia.
出版信息
Aliment Pharmacol Ther. 2020 Aug;52(3):569-570. doi: 10.1111/apt.15814. Epub 2020 Jun 3.
Abstract
LINKED CONTENT This article is linked to Taxonera et al papers. To view these articles, visit https://doi.org/10.1111/apt.15804 and https://doi.org/10.1111/apt.15893.
摘要
相关内容 本文与 Taxonera 等人的论文相关联。要查看这些文章，请访问 https://doi.org/10.1111/apt.15804 和 https://doi.org/10.1111/apt.15893.
相似文献
1
Letter: intestinal inflammation, COVID-19 and gastrointestinal ACE2-exploring RAS inhibitors.信件：肠道炎症、COVID-19 和胃肠道 ACE2-探索 RAS 抑制剂。
Aliment Pharmacol Ther. 2020 Aug;52(3):569-570. doi: 10.1111/apt.15814. Epub 2020 Jun 3.
2
Letter: ACE2, IBD and COVID-19-why IBD patients may be at reduced risk of COVID-19.信：ACE2、IBD 和 COVID-19-为什么 IBD 患者可能患 COVID-19 的风险较低。
Aliment Pharmacol Ther. 2020 Oct;52(8):1422-1423. doi: 10.1111/apt.16063.
3
Gastrointestinal ACE2, COVID-19 and IBD: Opportunity in the Face of Tragedy?胃肠道中的血管紧张素转换酶2、2019冠状病毒病与炎症性肠病：悲剧面前的机遇？
Gastroenterology. 2020 Oct;159(4):1623-1624.e3. doi: 10.1053/j.gastro.2020.04.051. Epub 2020 Apr 27.
4
Age, Inflammation, and Disease Location Are Critical Determinants of Intestinal Expression of SARS-CoV-2 Receptor and in Inflammatory Bowel Disease.年龄、炎症和疾病部位是炎症性肠病中 SARS-CoV-2 受体肠道表达的关键决定因素。
Gastroenterology. 2020 Sep;159(3):1151-1154.e2. doi: 10.1053/j.gastro.2020.05.030. Epub 2020 May 12.
5
Reply to Letter to the Editor: "COVID-19: is the ACE2 just a foe?".致编辑的信的回复：“COVID-19：血管紧张素转换酶2只是敌人吗？”
Am J Physiol Lung Cell Mol Physiol. 2020 May 1;318(5):L1031. doi: 10.1152/ajplung.00134.2020.
6
Letter: SARS-CoV-2-induced gastrointestinal inflammation.信件：SARS-CoV-2 诱导的胃肠道炎症。
Aliment Pharmacol Ther. 2020 Dec;52(11-12):1748-1749. doi: 10.1111/apt.16087.
7
Could DIZE be the answer to COVID-19?二氢杨梅素（DIZE）会是新冠病毒病（COVID-19）的解决方案吗？
Maturitas. 2020 Oct;140:83-84. doi: 10.1016/j.maturitas.2020.07.002. Epub 2020 Jul 2.
8
Blockade of SARS-CoV-2 infection by recombinant soluble ACE2.重组可溶性血管紧张素转换酶2对严重急性呼吸综合征冠状病毒2感染的阻断作用
Kidney Int. 2020 Jun;97(6):1091-1093. doi: 10.1016/j.kint.2020.04.009. Epub 2020 Apr 14.
9
Human recombinant soluble ACE2 (hrsACE2) shows promise for treating severe COVID-19.人重组可溶性血管紧张素转换酶2（hrsACE2）在治疗重症新型冠状病毒肺炎方面显示出前景。
Signal Transduct Target Ther. 2020 Nov 3;5(1):258. doi: 10.1038/s41392-020-00374-6.
10
COVID-19: is the ACE2 just a foe?新型冠状病毒肺炎：血管紧张素转换酶2只是一个“敌人”吗？
Am J Physiol Lung Cell Mol Physiol. 2020 May 1;318(5):L1025-L1026. doi: 10.1152/ajplung.00119.2020. Epub 2020 Apr 1.
引用本文的文献
1
The angiotensin receptor blocker, losartan, reduces inflammation and fibrosis, and prevents relapse of fibrosis after steroid-induced remission, in mice prone to Crohn's disease-like ileitis.在易患克罗恩病样回肠炎的小鼠中，血管紧张素受体阻滞剂氯沙坦可减轻炎症和纤维化，并防止类固醇诱导缓解后纤维化复发。
J Crohns Colitis. 2025 Jun 4;19(6). doi: 10.1093/ecco-jcc/jjaf083.
2
Can natural products modulate cytokine storm in SARS-CoV2 patients?天然产物能否调节新冠病毒患者的细胞因子风暴？
Biotechnol Rep (Amst). 2022 Sep;35:e00749. doi: 10.1016/j.btre.2022.e00749. Epub 2022 Jun 9.
3
Inhibitory effects of and on pro-inflammatory cytokines: A review.[具体物质]和[具体物质]对促炎细胞因子的抑制作用：综述。
Iran J Basic Med Sci. 2022 Mar;25(3):268-275. doi: 10.22038/IJBMS.2022.60954.13494.
4
Gut microbiota, angiotensin-converting enzyme, celiac disease, and risk of COVID-19 infection: a review.肠道微生物群、血管紧张素转换酶、乳糜泻与新型冠状病毒肺炎感染风险：综述
Gastroenterol Hepatol Bed Bench. 2021 Fall;14(Suppl1):S24-S31.
5
Anti-SARS-CoV-2 immunoglobulin profile in patients with celiac disease living in a high incidence area.在高发地区居住的乳糜泻患者的抗 SARS-CoV-2 免疫球蛋白特征。
Dig Liver Dis. 2022 Jan;54(1):3-9. doi: 10.1016/j.dld.2021.08.027. Epub 2021 Sep 10.
6
Is multisystem inflammatory syndrome related with coronavirus disease 2019, Kawasaki disease, and angiotensin-converting enzyme 2 in children?儿童多系统炎症综合征与2019冠状病毒病、川崎病及血管紧张素转换酶2有何关联？
Clin Exp Pediatr. 2021 May;64(5):225-226. doi: 10.3345/cep.2021.00031. Epub 2021 Mar 5.
7
Implications of SARS-CoV-2 infection for neurogastroenterology.严重急性呼吸综合征冠状病毒 2 感染对神经胃肠病学的影响。
Neurogastroenterol Motil. 2021 Mar;33(3):e14104. doi: 10.1111/nmo.14104. Epub 2021 Feb 16.
8
Can limonene be a possible candidate for evaluation as an agent or adjuvant against infection, immunity, and inflammation in COVID-19?柠檬烯能否作为一种评估用于对抗新冠病毒感染、免疫和炎症的药物或佐剂的可能候选物？
Heliyon. 2020 Dec 11;7(1):e05703. doi: 10.1016/j.heliyon.2020.e05703. eCollection 2021 Jan.
9
Applications of Non-invasive Neuromodulation for the Management of Disorders Related to COVID-19.非侵入性神经调节在COVID-19相关疾病管理中的应用
Front Neurol. 2020 Nov 25;11:573718. doi: 10.3389/fneur.2020.573718. eCollection 2020.
10
Letter: SARS-CoV-2-induced gastrointestinal inflammation.信件：SARS-CoV-2 诱导的胃肠道炎症。
Aliment Pharmacol Ther. 2020 Dec;52(11-12):1748-1749. doi: 10.1111/apt.16087.
本文引用的文献
1
2019 novel coronavirus disease (COVID-19) in patients with inflammatory bowel diseases.2019 新型冠状病毒病（COVID-19）合并炎症性肠病患者。
Aliment Pharmacol Ther. 2020 Jul;52(2):276-283. doi: 10.1111/apt.15804. Epub 2020 Jun 7.
2
Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Covid-19.肾素-血管紧张素-醛固酮系统抑制剂与新冠病毒风险。
N Engl J Med. 2020 Jun 18;382(25):2441-2448. doi: 10.1056/NEJMoa2008975. Epub 2020 May 1.
3
Renin-Angiotensin-Aldosterone System Blockers and the Risk of Covid-19.肾素-血管紧张素-醛固酮系统阻滞剂与新冠病毒风险。
N Engl J Med. 2020 Jun 18;382(25):2431-2440. doi: 10.1056/NEJMoa2006923. Epub 2020 May 1.
4
Gastrointestinal ACE2, COVID-19 and IBD: Opportunity in the Face of Tragedy?胃肠道中的血管紧张素转换酶2、2019冠状病毒病与炎症性肠病：悲剧面前的机遇？
Gastroenterology. 2020 Oct;159(4):1623-1624.e3. doi: 10.1053/j.gastro.2020.04.051. Epub 2020 Apr 27.
5
Faecal calprotectin indicates intestinal inflammation in COVID-19.粪便钙卫蛋白提示新冠病毒感染患者存在肠道炎症。
Gut. 2020 Aug;69(8):1543-1544. doi: 10.1136/gutjnl-2020-321388. Epub 2020 Apr 20.
6
Evidence for Gastrointestinal Infection of SARS-CoV-2.新型冠状病毒2019（SARS-CoV-2）胃肠道感染的证据。
Gastroenterology. 2020 May;158(6):1831-1833.e3. doi: 10.1053/j.gastro.2020.02.055. Epub 2020 Mar 3.
7
Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target.血管紧张素转换酶2（ACE2）作为严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的受体：分子机制与潜在治疗靶点
Intensive Care Med. 2020 Apr;46(4):586-590. doi: 10.1007/s00134-020-05985-9. Epub 2020 Mar 3.
8
Imbalance of the renin-angiotensin system may contribute to inflammation and fibrosis in IBD: a novel therapeutic target?肾素-血管紧张素系统失衡可能导致 IBD 的炎症和纤维化：一个新的治疗靶点？
Gut. 2020 May;69(5):841-851. doi: 10.1136/gutjnl-2019-318512. Epub 2019 Aug 13.
9
Angiotensin converting enzyme 2 activity and human atrial fibrillation: increased plasma angiotensin converting enzyme 2 activity is associated with atrial fibrillation and more advanced left atrial structural remodelling.血管紧张素转换酶 2 活性与人类心房颤动：血浆血管紧张素转换酶 2 活性增加与心房颤动和更严重的左心房结构重构相关。
Europace. 2017 Aug 1;19(8):1280-1287. doi: 10.1093/europace/euw246.
10
Age- and gender-related difference of ACE2 expression in rat lung.大鼠肺中血管紧张素转换酶2（ACE2）表达的年龄和性别相关差异。
Life Sci. 2006 Apr 4;78(19):2166-71. doi: 10.1016/j.lfs.2005.09.038. Epub 2005 Nov 21.
Zotero 插件